Pancreatic cancer study failure cripples a Merrimack drug, forcing a coup de grâce and pipeline retreat

Eighteen months after Merrimack $MACK restructured, selling off its one marketed drug, switching out CEOs and circling the wagons around three key cancer drugs, the biotech has been forced to scuttle one of its priority drug programs.